Anti-CD79B antibodies and immunoconjugates and methods of use

US8545850B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Yvonne Chen · San Mateo, US
• Mark S. Dennis · South San Francisco, US
• David Dornan · San Mateo, US
• Kristi Elkins · San Francisco, US
• Jagath Reddy Junutula · Fremont, US
• Andrew Polson · San Francisco, US
• Bing Zheng · Mountain View, US

Key dates

• Filing date: Nov 5, 2010
• Grant date: Oct 1, 2013
• Expiry date: Nov 5, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.